Tag Directory / DIAGNOSTICS     showing 21–40 of 43   RSS



Genital herpes rising in England, despite overall drop in STIs

bbc - STIs are particularly common among young people, with health experts saying testing for them is vital.

AI Summary: Public-health surveillance shows genital herpes cases climbing in England even as many other sexually transmitted infections fall. Experts warn the uptick signals gaps in prevention, testing and sexual-health services, underscoring the need for better awareness and targeted care rather than assuming the problem will fix itself. Yes, herpes is back on the agenda.

28 days / newscientist

28 days / bbc

28 days / bbc

6 wks / oncodaily

6 wks / bbc




Argentina expands hantavirus probe, sending teams to trap and test rats in Mendoza

medicalxpress - Argentina on Friday said it was expanding its investigation into the origins of the hantavirus outbreak that struck an Atlantic cruise ship last month, sending scientists to trap and test rats in the western province of Mendoza while lab results are pendi…

AI Summary: Argentinian health authorities have expanded an investigation in Mendoza after hantavirus concerns, dispatching teams to trap and test wild rodents for infection. The stepped-up fieldwork aims to map viral reservoirs and potential human exposure, while officials warn residents to take basic precautions — because nothing says 'welcome to town' like a rat-capture detail.

4 wks / abcnews

5 wks / abcnews




WellSpan Health, Philips launch 7-year AI, imaging partnership

Naomi Diaz / beckershospitalreview - York, Pa.-based WellSpan Health and Royal Philips have entered a seven-year strategic alliance covering advanced imaging technology, AI-enabled care and a joint research and co-development agreement across WellSpan’s 12 hospitals, diagnostic imaging cente…

AI Summary: WellSpan Health and Philips announced a seven-year collaboration to co-develop and deploy AI-enabled imaging solutions across the health system. The agreement aims to accelerate diagnostic imaging innovation, integrate AI into clinical workflows and support research — effectively a bet that smarter machines can shave time off scans and maybe improve patient outcomes.




LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC

oncodaily - LIBRETTO-432 Trial was presented during ASCO 2026 by Jonathan W. Goldman, MD, as a global, multicenter, phase 3, double-blind, randomized, placebo-controlled study evaluating adjuvant selpercatinib in patients with early-stage RET […]

AI Summary: At ASCO26 plenary, LIBRETTO‑432 data show adjuvant selpercatinib markedly prolongs event‑free survival and slashes recurrence risk for patients with stage II–IIIA RET fusion–positive non‑small cell lung cancer after curative treatment. The findings support a new standard for this rare genetic subgroup and press the case for routine genomic testing.

4 wks / oncodaily

4 wks / oncodaily

5 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / esmo

6 wks / oncodaily

6 wks / oncodaily




OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer

oncodaily - OPTIMA is one of the most important de-escalation studies presented at the 2026 ASCO Annual Meeting, because it addresses a daily clinical dilemma in early breast cancer: which patients truly […]

AI Summary: The OPTIMA trial demonstrated that using the Prosigna genomic test to select low‑risk ER+/HER2− early breast cancer patients allows omission of adjuvant chemotherapy without compromising disease control. The de‑escalation approach reduced exposure to chemo toxicity and supports molecular risk stratification to spare large numbers of patients unnecessary treatment — elegant, evidence‑based thrift.

5 wks / oncodaily

5 wks / oncodaily

5 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / bbc

7 wks / oncodaily




DESTINY-Lung03: T-DXd Confirms Activity in HER2-Overexpressing NSCLC, but Triplet Therapy Falls Short

oncodaily - DESTINY-Lung03 Part 1 provides an important signal for the treatment of HER2-overexpressing non-small cell lung cancer (NSCLC). The study confirms that trastuzumab deruxtecan (T-DXd) monotherapy has clinically meaningful activity in […]

AI Summary: DESTINY‑Lung03 data confirmed trastuzumab deruxtecan has tangible activity in HER2‑overexpressing non‑small‑cell lung cancer, producing notable responses. Attempts to escalate to triplet regimens failed to add benefit, prompting a reality check on combination complexity and the need for sharper biomarkers rather than more drugs.

5 wks / oncodaily

5 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

7 wks / nature

7 wks / oncodaily




New Tool That Tracks How the Brain Removes Waste Could Offer Clues About Alzheimer’s

discovermagazine - Learn why understanding how the brain clears its waste could help researchers combat neurodegenerative diseases and age-related cognitive decline.

AI Summary: Researchers unveiled an imaging tool that tracks how the brain removes metabolic waste, mapping preferred drainage routes and pinpointing breakdowns associated with Alzheimer’s pathology. The technique could flag early clearance failure years before symptoms, offering potential biomarkers and therapeutic targets—because sometimes the answer to dementia is less about neurons and more about the plumbing.




American Cancer Society Updates Colorectal Cancer Screening Guideline: Major Changes Emphasize Blood-Based and At-Home Stool Testing

cancer - ACS researchers aim to reduce colorectal cancer deaths by offering options to improve screening participation

AI Summary: American Cancer Society revised colorectal screening guidelines, elevating at‑home stool testing and clarifying the role of blood‑based assays. Recommendations stress broader access to noninvasive stool tests while urging cautious, limited use of blood tests where appropriate, aiming to expand screening uptake without sacrificing diagnostic accuracy or overwhelming follow‑up resources.


ACS guideline update: expanding stool tests, cautious blood-test role

6 wks / cancer

6 wks / cancer

6 wks / oncodaily

7 wks / cancer

7 wks / cancer


Blood-based detection and ctDNA: trials shaping screening and treatment

6 wks / oncodaily

6 wks / oncodaily


All Other Stories

5 wks / oncodaily

6 wks / oncodaily




Simple blood test could lead to personalized lung cancer treatment

medicalxpress - A single blood test could help doctors predict how lung cancer patients will respond to treatment before therapy begins, researchers have found. University of Queensland-led research focused on non-small cell lung cancer (NSCLC), the most common form of t…

AI Summary: Researchers describe a circulating cell-free methylated DNA liquid biopsy that can detect and track lung cancer by reading tumor-specific methylation patterns in blood. The minimally invasive test aims to guide personalized treatment choices, enable earlier detection of recurrence, and reduce dependence on tissue biopsies—basically doing the diagnostic heavy lifting while you sip your coffee.


Blood tests for monitoring and personalizing lung cancer care

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily


MCED trials and clinical benefit debate

5 wks / oncodaily

5 wks / oncodaily

5 wks / oncodaily

6 wks / oncodaily


Methylation liquid biopsy methods and applications

6 wks / oncodaily

6 wks / oncodaily

7 wks / oncodaily

7 wks / nature


All Other Stories

5 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

6 wks / oncodaily

7 wks / oncodaily

7 wks / oncodaily




Smart ring maker Oura files confidentially for IPO as consumer demand propels revenue growth

fiercehealthcare - Oura, the smart ring maker, filed confidentially for an initial public offering after it reached an $11 billion valuation last year.

AI Summary: Ōura has quietly filed confidential paperwork to go public, leveraging surging consumer demand for its smart rings and an aggressive pivot into healthcare data and services. The company is pitching its wearable as a clinical-grade monitoring platform to insurers and providers, aiming to monetize sleep, activity and biometrics while navigating privacy and regulatory scrutiny.




Adding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer

Kathleen Medora / aacr - CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis PHILADELPHIA – A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic canc…

AI Summary: Researchers propose lowering the CA19‑9 threshold to identify additional patients at high risk for pancreatic cancer. The analysis indicates the new cutoff improves detection of potentially dangerous cases without an unmanageable rise in false positives, offering a straightforward diagnostic tweak that could prompt earlier workups and treatment decisions.

6 wks / oncodaily

6 wks / newscientist

7 wks / oncodaily

1 month / medicalxpress




Skin cancer cases hit record high in the UK

Sydney Ghazarian / cancerresearchuk - New analysis shows that melanoma skin cancer rates in the UK have reached a new high of 20,000 cases per yearThe post Skin cancer cases hit record high in the UK appeared first on Cancer Research UK - Cancer News.

AI Summary: The UK has recorded its highest-ever number of skin cancer cases, with an alarming rise in the most dangerous presentations. Public health experts point to changing sun behaviours and inadequate sun protection as likely contributors. The surge signals strain on dermatology services and a need for clearer messaging—because sunscreen confusion apparently remains a public health hobby.

7 wks / bbc

7 wks / oncodaily

7 wks / bbc




Canadian from hantavirus-hit cruise ship tests positive

bbc - The individual is one of four former passengers on the MV Hondius isolating on Vancouver Island, British Columbia.

AI Summary: A Canadian passenger tested positive after an Andes‑virus outbreak aboard a cruise ship, and French authorities report the strain matches known South American viruses. Public health teams began targeted testing, contact tracing and onboard monitoring as experts debate what constitutes “close contact,” balancing realistic containment with the mild panic such exotic pathogens tend to inspire.


Canada confirms hantavirus cases; testing and isolation underway

1 month / medicalxpress

1 month / medicalxpress

1 month / bbc


Defining close contact: contact‑tracing challenges and outbreaks at sea

1 month / medicalxpress

1 month / livescience


Sequencing shows South American strain; ship arrival and WHO stance

1 month / medicalxpress

1 month / abcnews

1 month / medicalxpress


All Other Stories

7 wks / abcnews

1 month / medicalxpress

1 month / medicalxpress

1 month / medicalxpress

1 month / abcnews

1 month / medicalxpress

1 month / abcnews


Back to Top / Sat, May 16, 2026, 4:21 pm / permalink 23910 / 24 stories in 1 month /



When should you get a mammogram? Conflicting advice makes it hard to know

medicalxpress - Deciding when to get routine mammograms is confusing. Some health groups recommend women begin at age 40 or 45 while another recently opted for age 50. They also differ on whether yearly or every other year is best.

AI Summary: Conflicting guidance about when to start and how often to perform mammography continues to confuse patients and clinicians, complicating shared decision‑making. Experts urge individualized risk assessment and clearer communication of benefits and harms to reduce both undertreatment and unnecessary anxiety, because apparently screening schedules enjoy being controversial.


Patient confusion over mammogram timing

1 month / medicalxpress

1 month / abcnews


Risk-based screening: AI and trials

7 wks / nature

1 month / oncodaily


USPSTF political shake-up threatens screening guidance

1 month / abcnews


All Other Stories

6 wks / bbc

6 wks / bbc


Back to Top / Sat, May 16, 2026, 4:21 pm / permalink 23911 / 12 stories in 1 month /



FDA clears 1st AI sepsis monitoring tool

Giles Bruce / beckershospitalreview - A tool from tech company Bayesian Health has become the first continuous AI sepsis monitor to gain FDA approval. The solution monitors hospital patients to detect deterioration and flag sepsis early on. The application was developed at Baltimore-based Joh…

AI Summary: Regulators have cleared the first AI‑driven sepsis early‑warning system for clinical deployment, enabling hospitals to use algorithmic alerts to identify patients at risk of deterioration earlier. The clearance opens the door for broader adoption of AI in acute care while renewing debates about clinical oversight, false alarms and integration into existing workflows.

1 month / nature

2 months / medicalxpress




PCOS has been officially renamed PMOS, and it’s a momentous move

newscientist - PCOS will now be known as PMOS (polyendocrine metabolic ovarian syndrome), and for Alice Klein, who has the conditon, it's been a long time coming

AI Summary: Medical experts have rebranded polycystic ovary syndrome as "polyendocrine metabolic ovarian syndrome" (PMOS) to better reflect its metabolic and endocrine drivers and improve diagnosis and treatment for about 170 million affected women worldwide. The change follows years of debate over an inaccurate name and aims to reduce misdiagnosis and guide more targeted care—because calling it something sensible might actually help.

1 month / oncodaily

1 month / livescience

1 month / medicalxpress

1 month / medicalxpress

1 month / medicalxpress

1 month / livescience

2 months / medicalxpress

2 months / newscientist

2 months / livescience


Back to Top / Tue, May 12, 2026, 9:22 am / permalink 23628 / 10 stories in 2 months /



Study reveals how parenting styles shape babies' willingness to help others

medicalxpress - New research from Durham University shows that the way parents instruct and encourage infants to help plays a key role in how helping behavior develops, and that these approaches vary across cultures.

AI Summary: The RESET‑C trial tested one preoperative dose of pembrolizumab in localized mismatch repair‑deficient colon cancer and recorded unexpectedly high tumor responses, with several patients remaining cancer‑free for nearly three years. The dramatic neoadjuvant activity suggests immune priming could reshape perioperative strategies and raises questions about surgery timing and organ preservation.

1 month / oncodaily

1 month / oncodaily

2 months / nature

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress

2 months / sciencedaily


Back to Top / Mon, May 11, 2026, 2:21 am / permalink 23550 / 8 stories in 2 months /



FDA approves blood test to guide breast cancer therapy

Ella Jeffries / beckershospitalreview - The FDA has approved a companion diagnostic from Guardant Health to identify patients eligible for treatment with a targeted therapy developed by Pfizer and Arvinas. The blood-based test detects ESR1 mutations in patients with estrogen receptor-positive, …

AI Summary: The FDA approved a blood‑based test to help guide breast cancer treatment selection, authorizing a diagnostic that identifies patients more likely to benefit from specific therapies. The move could reduce unnecessary treatments and sharpen precision oncology, though broad clinical adoption will depend on further validation, payer coverage and clinician trust.


ESMO Breast highlights and expert commentary

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily


FDA clearances reshape diagnostics and therapies

2 months / medicalxpress

2 months / medicalxpress


Liquid biopsy, mutations and treatment resistance

2 months / nature

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily


All Other Stories

1 month / oncodaily

1 month / medicalxpress

2 months / oncodaily

2 months / medicalxpress

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress

2 months / oncodaily

2 months / esmo

2 months / nature


Back to Top / Sat, May 9, 2026, 5:21 am / permalink 23499 / 23 stories in 2 months /



National study examines genetic testing to inform follow-up care for cancer survivors

medicalxpress - Hundreds of thousands of people diagnosed with cancer are still alive today but were never genetically tested, either because testing was not available or was not routinely offered at the time of their diagnosis. These patients are just as likely as those…

AI Summary: A national study has been launched to assess whether genetic testing can refine follow-up care for cancer survivors, tailoring surveillance to individual risk and potentially reducing unnecessary tests. The large-scale effort seeks to integrate genomic data into survivorship plans to better predict late effects and allocate resources to those most likely to benefit.


Building survivorship standards, care and advocacy

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily


Conferences, research and personalized cancer survivorship insights

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily


National genetic-testing study and genomic implications for survivors

2 months / oncodaily

2 months / medicalxpress

2 months / medicalxpress

2 months / esmo


All Other Stories

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / nature

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress

2 months / oncodaily

2 months / medicalxpress

2 months / oncodaily

2 months / medicalxpress


Back to Top / Sat, May 9, 2026, 12:21 am / permalink 23486 / 49 stories in 2 months /



3 Dead in Hantavirus Outbreak Aboard Cruise Ship, W.H.O. Says

Alexandra E. Petri / nytimes - One case of the infection has been confirmed in a laboratory, and there are five additional suspected cases, the organization said on Sunday.

AI Summary: A suspected hantavirus outbreak on an Atlantic cruise ship has been linked to three deaths, prompting a WHO-led investigation and urgent public-health follow-up. Authorities are coordinating testing, contact tracing and onboard inspections while reminding the public that hantaviruses are typically rodent-borne and can cause severe respiratory illness if unchecked.


Hantavirus basics and cruise outbreak risks

2 months / medicalxpress

2 months / discovermagazine

2 months / livescience

2 months / abcnews

2 months / medicalxpress


Stranded MV Hondius: passengers and routing

2 months / bbc

2 months / bbc

2 months / abcnews


WHO probes deaths, possible human transmission

2 months / newscientist

2 months / bbc

2 months / abcnews


All Other Stories

2 months / discovermagazine

2 months / medicalxpress

2 months / medicalxpress

2 months / abcnews

2 months / medicalxpress

2 months / abcnews

2 months / kffhealthnews

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / livescience

2 months / medicalxpress

2 months / abcnews

2 months / medicalxpress

2 months / medicalxpress

2 months / abcnews

2 months / oncodaily

2 months / medicalxpress

2 months / livescience

2 months / medicalxpress

2 months / medicalxpress

2 months / abcnews

2 months / abcnews

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / bbc

2 months / medicalxpress

2 months / bbc

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / abcnews

2 months / abcnews

2 months / medicalxpress

2 months / livescience

2 months / medicalxpress

2 months / medicalxpress

2 months / kffhealthnews

2 months / abcnews

2 months / abcnews

2 months / abcnews

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / bbc

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / bbc

2 months / medicalxpress

2 months / medicalxpress

2 months / newscientist

2 months / livescience

2 months / bbc

2 months / medicalxpress

2 months / bbc

2 months / medicalxpress

2 months / medicalxpress

2 months / bbc

2 months / medicalxpress

2 months / livescience

2 months / abcnews

2 months / abcnews

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / bbc

2 months / bbc

2 months / bbc

2 months / abcnews

2 months / bbc

2 months / bbc

2 months / abcnews

2 months / abcnews

2 months / abcnews


Back to Top / Mon, May 4, 2026, 1:21 am / permalink 23159 / 119 stories in 2 months /



Back to Top


DIAGNOSTICS Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Digital Health, Drug Pricing, Clinical Trials, Research Funding and look for the RSS link.


NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.